SGCM
ALXN

Sand Grove Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Sand Grove Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-717,127
Closed -$132M – 21
2021
Q2 		$132M Sell
717,127
-350,264
-33% -$60.1M 12.46% 4
2021
Q1 		$163M Buy
1,067,391
+797,391
+295% +$123M 15.91% 2
2020
Q4 		$42.2M Buy
+270,000
New +$34.7M 13.14% 4

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Sand Grove Capital Management's ALXN Position: Q3 2021 in Review

Sand Grove Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 717,127 shares — an estimated $132M sold.

Sand Grove Capital Management first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $163M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Sand Grove Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Sand Grove Capital Management sold 717,127 Alexion Pharmaceuticals shares in Q3 2021, an estimated $132M.
  • Sand Grove Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Sand Grove Capital Management's Alexion Pharmaceuticals position peaked at $163M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Sand Grove Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.